Hydroxytoluic acid
CAS No. 83-40-9
Hydroxytoluic acid( Hydroxytoluic acid | NSC 17561 | NSC17561 | NSC-17561 )
Catalog No. M16090 CAS No. 83-40-9
The salts or esters of salicylic acids, or salicylate esters of an organic acid.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | 27 | In Stock |
|
Biological Information
-
Product NameHydroxytoluic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe salts or esters of salicylic acids, or salicylate esters of an organic acid.
-
DescriptionThe salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.
-
In Vitro——
-
In Vivo——
-
SynonymsHydroxytoluic acid | NSC 17561 | NSC17561 | NSC-17561
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number83-40-9
-
Formula Weight152.15
-
Molecular FormulaC8H8O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESCC1=C(O)C(C(O)=O)=CC=C1
-
Chemical Name2,3-Cresotic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
DuP-697
DuP-697 is an irreversible, specific COX-2 inhibitor with IC50 values ??of 10 nM and 800 nM for human COX-2 and COX-1. DuP-697 also exhibits anti-angiogenic, anti-inflammatory, antipyretic and apoptotic effects.
-
SC 58125
SC-58125 is a selective cyclooxygenase 2 (COX-2) inhibitor,?with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo, and it also can inhibit edema at the inflammatory site and is analgesicSC-58125 treatment on the growth of human colon carcinoma cells in nude mice.?
-
Orientin
Orientin may be regarded as a candidate therapeutic agent for treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.
Cart
sales@molnova.com